Serine protease inhibitor Kazal-type 1 (SPINK1)

Serine protease inhibitor Kazal-type 1 (SPINK1) is a small, secreted protein produced primarily by pancreatic acinar cells, acting as an essential inhibitor of trypsin. Its physiological role is to prevent autodigestion of the pancreas by blocking prematurely activated trypsin within zymogen granules and ducts. Loss-of-function mutations in SPINK1 predispose individuals to several forms of pancreatitis, with the most widely studied N34S mutation linked to increased disease risk. Beyond the pancreas, SPINK1 is also known as tumor-associated trypsin inhibitor (TATI) and plays a role in cancer biology by promoting cell survival, proliferation, and metastasis, especially via epidermal growth factor receptor (EGFR) signaling. SPINK1 is overexpressed in several cancers and serves as a biomarker for poor prognosis and aggressive disease subtypes. Although no direct therapeutic agents currently target SPINK1, it interacts with signaling pathways modulated by established drugs, such as EGFR inhibitors in oncology.

Other names

Pancreatic secretory trypsin inhibitorTumor-associated trypsin inhibitorPSTITATISpink3PCTTTCP

Competitive inhibition of trypsin, binding to and blocking the active site, rendering the enzyme inactive. Activation of EGFR signaling pathways in cancer models, driving proliferation and survival. Inhibition of granzyme A activity in tumor cells, preventing apoptosis. Potential involvement in cellular plasticity and resistance to chemotherapy via indirect pathways.